A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90 Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study.
Armeen MahvashSteven ChartierMark TurcoPaula HabibSteven GriffithScott BrownSrinivasan Cheenu KappadathPublished in: BMC gastroenterology (2022)
Clinicaltrials.gov; NCT04736121; date of 1st registration, January 27, 2021, https://clinicaltrials.gov/ct2/show/NCT04736121 .